Management of Gout
Authors: Paul G. Shekelle, Sydne J. Newberry
Journal: Annals of Internal Medicine (2017)

Letters6 June 2017Management of GoutPaul G. Shekelle, MD, PhD and Sydne J. Newberry, PhDPaul G. Shekelle, MD, PhDFrom West Los Angeles VA Medical Center, Los Angeles, and RAND Corporation, Santa Monica, California.Search for more papers by this author and Sydne J. Newberry, PhDFrom West Los Angeles VA Medical Center, Los Angeles, and RAND Corporation, Santa Monica, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0212 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Our search identified the randomized controlled trial of pegloticase (1). However, we excluded it because our review focused on the management of gout in primary care and pegloticase was considered to be a drug that primary care physicians do not use. We included Becker and colleagues' article (2) in both the review (reference 91) and the evidence report (reference 118). In that study, a post hoc analysis revealed the association between serum urate level achieved and reduction in tophi size achieved at week 52; we therefore did not consider it to be hypothesis-testing.References1. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711-20. [PMID: 21846852] doi:10.1001/jama.2011.1169 CrossrefMedlineGoogle Scholar2. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-61. [PMID: 16339094] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From West Los Angeles VA Medical Center, Los Angeles, and RAND Corporation, Santa Monica, California.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-0461. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoManagement of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians Amir Qaseem , Russell P. Harris , Mary Ann Forciea , and Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline Paul G. Shekelle , Sydne J. Newberry , John D. FitzGerald , Aneesa Motala , Claire E. O'Hanlon , Abdul Tariq , Adeyemi Okunogbe , Dan Han , and Roberta Shanman Management of Gout Jasvinder A. Singh and Kenneth G. Saag Metrics Cited byNitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studiesEfficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: A systematic review and meta‑analysis 6 June 2017Volume 166, Issue 11Page: 855KeywordsDisclosureDrugsGoutPrimary care physiciansUric acid ePublished: 6 June 2017 Issue Published: 6 June 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...